Amneal Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.: SG&A Expense Trends

SG&A Expenses: Amneal vs. Wave Life Sciences

__timestampAmneal Pharmaceuticals, Inc.Wave Life Sciences Ltd.
Wednesday, January 1, 2014846150002999000
Thursday, January 1, 201510967900010393000
Friday, January 1, 201611875700015994000
Sunday, January 1, 201710904600026975000
Monday, January 1, 201823043500039509000
Tuesday, January 1, 201928959800048869000
Wednesday, January 1, 202032672700042510000
Friday, January 1, 202136550400046105000
Saturday, January 1, 202239970000050513000
Sunday, January 1, 202342967500051292000
Loading chart...

Infusing magic into the data realm

SG&A Expense Trends: Amneal Pharmaceuticals vs. Wave Life Sciences

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. Over the past decade, Amneal Pharmaceuticals, Inc. and Wave Life Sciences Ltd. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amneal's SG&A expenses surged by over 400%, reflecting a strategic expansion and increased operational activities. In contrast, Wave Life Sciences exhibited a more modest growth of approximately 1,600%, indicating a steady yet cautious approach to scaling operations.

Amneal's expenses peaked in 2023, reaching nearly five times their 2014 levels, while Wave Life Sciences maintained a consistent upward trajectory, albeit at a slower pace. These trends highlight the contrasting business models and growth strategies of these two companies, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025